Trials / Unknown
UnknownNCT05873400
Effect of Renin Angiotensin Aldosterone System Genetic Polymorphism on the Pharmacological Effect of Mineralocorticoid Receptor Antagonists in Patients With Myocardial Infarction
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 102 (estimated)
- Sponsor
- Ain Shams University · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- —
Summary
Early treatment of Myocardial Infarction patients with mineralocorticoid receptor antagonist with help reduces the incidence of cardiac remodeling and development into heart failure. Also studying aldosterone synthase (CYP11B2) and mineralocorticoid receptor (NR3C2) gene polymorphisms in Egyptian Myocardial Infarction patients will help tailor medication therapy and optimize therapeutic effects with the least adverse effects.
Conditions
Timeline
- Start date
- 2022-08-01
- Primary completion
- 2023-12-01
- Completion
- 2024-04-01
- First posted
- 2023-05-24
- Last updated
- 2023-05-24
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT05873400. Inclusion in this directory is not an endorsement.